Efficacy and safety of oral immunotherapy combination with omalizumab for severe cow's milk allergy- follow up study
Not Applicable
- Conditions
- food allergy
- Registration Number
- JPRN-UMIN000024397
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Children who have acute disease and chronic disease except allergic disease. 2.Children or guardian who deny the study 3. Children who were judged as inappropriate by the study director
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentages of sustained unresponsiveness at the months 18 after the start of the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy
- Secondary Outcome Measures
Name Time Method The frequencies of allergic reactions from the start to the months 18 after the randomized study of oral immunotherapy combination with omalizumab for severe cow's milk allergy